Indivior Pharmaceuticals (INDV) Other Accumulated Expenses (2023 - 2026)

Indivior Pharmaceuticals' Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $14.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 366.67% year-over-year to $14.0 million; the TTM figure through Mar 2026 stood at $14.0 million (up 366.67% YoY), while the FY2025 annual figure was $42.0 million, down 57.58% from the prior year.
• Other Accumulated Expenses was $14.0 million for Q1 2026 at Indivior Pharmaceuticals, down from $42.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $492.0 million in Q4 2023 to a low of $3.0 million in Q1 2025.
• Historically, Other Accumulated Expenses has averaged $123.0 million across 4 years, with a median of $99.0 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Other Accumulated Expenses sank 79.88% in 2024, then jumped 366.67% in 2026.
• A 4-year view of Other Accumulated Expenses shows it stood at $492.0 million in 2023, then tumbled by 79.88% to $99.0 million in 2024, then slumped by 57.58% to $42.0 million in 2025, then tumbled by 66.67% to $14.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $14.0 million (Q1 2026), $42.0 million (Q4 2025), and $106.0 million (Q3 2025), per Business Quant data.